How does CBD work? Mechanisms of action of cannabidiol in 2026

Cannabidiol (CBD) is one of the most intensively studied natural molecules of the last decade. The number of scientific publications indexed in PubMed with the term "cannabidiol" has exceeded 10,000 entries, with an annual growth rate of about 1,500 articles (PubMed, 2024). The question "how does CBD work" no longer has a simple answer.

CBD is not a "one receptor ligand". Pharmacological reviews describe over 65 molecular targets with which this molecule interacts (Frontiers in Pharmacology, 2020). This is polypharmacology in its purest form. CBD modulates the endocannabinoid system, serotoninergic system, vanilloid system, opioid system, glycinergic system, and transcription factors PPAR.

In this article, we explain the mechanism of action of CBD layer by layer. We start with the endocannabinoid system (ECS), delve into the pharmacology of individual receptors, explain the difference between CBD and THC, discuss pharmacokinetics and bioavailability. We focus on what has been confirmed by clinical and preclinical studies, rather than marketing simplifications.

KEY INFORMATION
– CBD does not directly activate the CB1 receptor, which is why it does not produce a psychoactive effect like THC. It acts as a negative allosteric modulator of CB1/CB2 (British Journal of Pharmacology, 2015).
– Main molecular targets of CBD: ECS (via FAAH), 5-HT1A receptor, TRPV1, GPR55, PPARγ, alpha-3 glycine receptor.
– Inhibition of FAAH increases anandamide levels by up to 106% (Translational Psychiatry, 2012).
– Bioavailability: 6% orally, 13-19% sublingually, 11-45% inhaled.
– CBD inhibits CYP3A4 and CYP2C9, affecting the metabolism of about 60% of medications (PMC, 2019).

What is the endocannabinoid system and how does it affect health?

The endocannabinoid system (ECS) is a signaling network identified in 1992, comprising receptors, endogenous ligands, and enzymes that regulate the body's homeostasis (British Journal of Pharmacology, 2006). The ECS regulates sleep, appetite, mood, pain, memory, immune response, and thermoregulation. It is a system that "tunes" other neural pathways.

The ECS consists of three basic components. The first is endocannabinoids, namely anandamide (AEA) and 2-arachidonoylglycerol (2-AG). The second is receptors, primarily CB1 and CB2. The third is metabolic enzymes: FAAH breaks down anandamide, while MAGL breaks down 2-AG. Together, they function like a neurochemical thermostat.

Why is ECS important for understanding how CBD works? Because CBD is not just a "cannabis add-on". It engages in dialogue with our own endocannabinoid system. It does not activate it as forcefully as THC, but gently modulates the flow of signals. This is the difference between pressing the gas pedal and making a slight adjustment to the steering wheel.

Studies show that over 40% of the population may have what is known as endocannabinoid deficiency (Cannabis and Cannabinoid Research, 2016). Symptoms include chronic pain, migraines, irritable bowel syndrome, anxiety, insomnia. The "clinical endocannabinoid deficiency" hypothesis formulated by Russo explains why cannabinoid supplementation improves well-being in some individuals.

Endocannabinoids: anandamide and 2-AG

Anandamide (from Sanskrit "ananda" – bliss) is the first identified endocannabinoid. It primarily binds to CB1 receptors in the central nervous system. It influences mood, motivation, and the sensation of pleasure. Its levels rise after intense physical exertion and are responsible for the so-called "runner's high."

2-AG (2-arachidonoylglycerol) is the second endocannabinoid, present in concentrations 100-1000 times higher than anandamide. It activates both CB1 and CB2. It participates in regulating immune responses, inflammatory states, and neuroprotection. Its levels increase during stress and tissue injury.

FAAH and MAGL enzymes ensure that endocannabinoids do not linger too long. FAAH breaks down anandamide within minutes of its release. MAGL does the same with 2-AG. CBD primarily inhibits FAAH, which in practice means prolonged action of anandamide in synapses.

CB1 and CB2 receptors – where are they located?

CB1 receptors are primarily found in the central nervous system: hippocampus, cerebral cortex, cerebellum, and basal ganglia. It is the most densely distributed G protein-coupled receptor in the brain. It is responsible for regulating memory, motor coordination, appetite, and pain perception. Activation of CB1 by THC produces a psychoactive effect.

CB2 receptors are mainly present in the peripheral nervous system and immune cells: T cells, B cells, macrophages, and microglia in the brain. They are responsible for modulating the inflammatory response and tissue regeneration. Their activation does not produce a psychoactive effect, even with strong stimulation by an agonist.

This distribution of receptors explains many clinical observations. CBD acts on the ECS indirectly, but its clinical effects relate to both the nervous system (anxiety, pain, sleep) and peripheral (inflammation, skin, joints). It is no coincidence that one compound can support such diverse scenarios.

The endocannabinoid system includes CB1 receptors in the CNS (the densest G protein-coupled receptor in the brain) and CB2 in peripheral tissues and immune cells, as well as endocannabinoids anandamide and 2-AG broken down by FAAH and MAGL enzymes (British Journal of Pharmacology, 2006). CBD modulates this system without directly activating the receptors.

Why does CBD not directly activate the CB1 receptor?

CBD has minimal orthosteric affinity for CB1. The Ki value for the human CB1 receptor is about 1-3 micromolar, which is several thousand times weaker than THC (British Journal of Pharmacology, 2015). In practice, this means that CBD almost does not hit the classic binding site for agonists on CB1. Hence the lack of psychoactive effect.

Instead, CBD acts as a so-called negative allosteric modulator of CB1 (NAM). It binds to a different site than a classic agonist and reduces the efficacy of THC or anandamide binding. It’s as if CBD gently presses the lock, making it harder for another compound to turn the key. The result is a weakening, not a strengthening of the signal.

Therefore, CBD can even suppress the action of THC when taken simultaneously. The study by Niesink and van Laar (2013) showed that cannabis strains with a higher CBD:THC ratio induce fewer psychotic effects in recreational users. This is a clinical consequence of negative allosteric modulation.

CBD acts similarly on CB2, although the mechanism is less well characterized. It is known to regulate CB2 activity in the inflammatory response without classical orthosteric activation. This is another layer of CBD's dialogue with the endocannabinoid system.

What does "allosteric modulator" mean?

An allosteric modulator is a molecule that binds to a receptor at a site other than the active site. It does not activate the receptor on its own but changes its sensitivity to the endogenous ligand. A positive modulator (PAM) amplifies the signal, while a negative modulator (NAM) weakens it. CBD is a NAM for CB1.

This mode of action has significant pharmacological advantages. There is no risk of "overactivation" of the receptor, as CBD only corrects the signal of the endogenous ligand. The effect is self-limiting – CBD cannot "force" a signal if anandamide is lacking. This fundamentally differs from classical agonists like THC.

In clinical practice, this means a better safety profile. The WHO in a 2018 review stated that CBD does not exhibit potential for addiction or significant risk of abuse (WHO, 2018). There is also no psychoactive effect, tolerance, or withdrawal syndrome at standard supplemental doses.

How do we know that CBD does not act like THC?

From numerous pharmacological studies in vitro and in vivo. Radioligand binding tests show that CBD displaces only 30-40% of bound THC from CB1 at therapeutic concentrations. Functional tests (GTP-gamma-S binding) show that CBD does not induce intracellular signaling through CB1, characteristic of agonists.

Clinically: studies with doses of CBD up to 1500 mg daily in healthy volunteers showed no psychoactive effects (WHO, 2018). These doses are many times higher than daily supplementation (20-50 mg). If CBD acted like THC, effects would be noticeable at such high amounts.

Unique observation: Allosteric modulation of CB1 by CBD is not a weakness, but its greatest strength. Classical agonists (like THC or synthetic cannabinoids) have a dose-effect curve that is "on or off". CBD provides an inverted U-shaped curve that self-limits at higher doses. This is the biological equivalent of "you cannot overdose in a way that increases the therapeutic effect," as confirmed by studies with CBD at doses of 300-900 mg in social anxiety.

How does CBD work through the 5-HT1A receptor?

The 5-HT1A receptor is a serotoninergic target responsible for regulating mood, anxiety, and body temperature. CBD acts as a positive allosteric modulator of 5-HT1A at concentrations starting from 100 nanomoles (Frontiers in Pharmacology, 2020). This is one of the key mechanisms explaining the anxiolytic and antidepressant effects of cannabidiol.

CBD's action on 5-HT1A resembles the mechanism of buspirone, an anxiolytic used to treat generalized anxiety. The difference: CBD does not induce the sedation typical of benzodiazepines, does not cause addiction, and does not produce withdrawal symptoms. This is why more and more people are turning to CBD as an alternative or complement to classical anxiolytic medications.

In a 2019 study, 57 men received CBD at a dose of 300 mg before a public speaking test. The CBD group showed significantly less increase in blood pressure and lower subjective anxiety than the placebo group (Frontiers in Pharmacology, 2019). Interestingly, doses of 150 mg and 600 mg produced weaker effects than 300 mg. This is a classic inverted U-curve.

Why exactly 300 mg? Because at low doses, the CBD signal through 5-HT1A is insufficient to achieve a clinical effect. At very high doses, CBD begins to additionally affect other receptors (including TRPV1 and adenosine transporters), which may negate the beneficial effect on 5-HT1A.

Anxiolysis and antidepressant action

A retrospective study from 2019 included 72 patients with anxiety and sleep disorders. After one month of CBD supplementation at 25-75 mg daily, 79.2% of participants reported reduced anxiety (The Permanente Journal, 2019). 66.7% reported improved sleep. The effect persisted for 3 months of observation.

The antidepressant mechanism also engages neurogenesis in the hippocampus. CBD increases BDNF (brain-derived neurotrophic factor) expression through the 5-HT1A-cAMP-CREB pathway. Animal studies have shown the antidepressant effect of CBD comparable to imipramine in the forced swimming test, but without sedation and anticholinergic effects.

The practical consequence: CBD is not a "depression medication" in the classical sense, but it can support therapy as an adjunct. It increases neuroplasticity in the hippocampus, modulates the hypothalamic-pituitary-adrenal (HPA) axis, and lowers cortisol levels by 15-20% in pharmacodynamic studies.

Can CBD replace antidepressants?

No. CBD is a supportive tool, not a substitute. Classical SSRIs and SNRIs have 40-60 years of clinical data and registered indications. CBD is in the exploratory research phase, without formal registration as an antidepressant. Discontinuing psychiatric medications without consulting a doctor can be dangerous.

However, CBD has an advantage in its side effect profile. It does not cause sexual dysfunction, weight gain, or the "emotional blunting" effect typical of SSRIs. For many people, this is an argument for integrating CBD into mental health support strategies, always after consulting a physician.

In a randomized study from 2019, 57 men received CBD at a dose of 300 mg before a public speaking simulation. The CBD group showed significantly less increase in blood pressure and lower subjective anxiety than the placebo group (Frontiers in Pharmacology, 2019). The anxiolytic effect of CBD is associated with positive allosteric modulation of the 5-HT1A receptor.

How does CBD affect the TRPV1 receptor and pain perception?

TRPV1 (transient receptor potential vanilloid type 1) is the same receptor activated by capsaicin in hot peppers. CBD acts as an agonist of TRPV1 at concentrations starting from 1 micromolar, causing initial activation and then desensitization of the receptor (Frontiers in Pharmacology, 2020). This mechanism is key to its analgesic action.

TRPV1 is mainly found in nociceptors, which are neurons that transmit pain signals. Activation of this receptor normally generates a pain signal. However, prolonged stimulation (e.g., by capsaicin or CBD) leads to desensitization: the receptor "shuts down" and stops responding. As a result, pain perception in the exposed area decreases.

This explains the effectiveness of topical CBD preparations (ointments, balms) in joint and muscle pain. A 2020 study on patients with peripheral neuropathy showed that topical CBD 250 mg daily reduced pain by 29.4% on the visual analog scale after 4 weeks (Current Pharmaceutical Biotechnology, 2020).

In addition to TRPV1, CBD also modulates the alpha-3 glycine receptor, which is responsible for neuropathic and chronic pain. The mechanism described by Xiong et al. (Journal of Experimental Medicine, 2012) shows that CBD enhances inhibitory glycinergic signaling in the spinal cord. This is a second pain-relieving pathway independent of the endocannabinoid system.

TRPV1 and temperature regulation and inflammatory states

TRPV1 is involved in thermoregulation. Activation causes a feeling of heat, while desensitization may lower cold tolerance. Therefore, some CBD users report a "mild warmth" after the first doses. This effect is temporary, disappearing within a week of regular supplementation.

Moreover, TRPV1 regulates the release of inflammatory mediators from sensory neurons (substance P, CGRP). Desensitization of TRPV1 by CBD reduces these secretions, which explains its anti-inflammatory action without classical cyclooxygenase blocking (like NSAIDs). This is an alternative pathway, free from the risk of stomach ulcers and kidney damage.

Alpha-3 glycine receptor and neuropathic pain

The alpha-3 glycine receptor is located in the dorsal horns of the spinal cord. It normally inhibits pain conduction at the spinal level. In neuropathic pain, its function is weakened by phosphorylation. CBD restores this function through an allosteric mechanism, independent of the endocannabinoid system.

Preclinical studies on neuropathic pain models have shown that CBD reduces allodynia and hyperalgesia at doses of 2.5-10 mg/kg. The effect was blocked in mice lacking the alpha-3 glycine receptor gene. This is evidence that the mechanism is indeed glycinergic, not just cannabinoid-based (Journal of Experimental Medicine, 2012).

CBD acts on the TRPV1 receptor as an agonist followed by desensitization, which reduces pain signaling in nociceptors. In a 2020 study, topical CBD 250 mg daily reduced neuropathic pain by 29.4% on the VAS scale after 4 weeks (Current Pharmaceutical Biotechnology, 2020). This complements the mechanism through the alpha-3 glycine receptor.

How does CBD inhibit FAAH and increase anandamide?

Inhibition of fatty acid amide hydrolase (FAAH) is one of the most significant indirect mechanisms of CBD. In the study by Leweke et al., CBD at a dose of 600-800 mg daily increased anandamide levels in the serum of patients with psychosis by 106% over 4 weeks (Translational Psychiatry, 2012). Higher anandamide levels correlated with a reduction in symptoms.

How does this work? FAAH is an enzyme located in intracellular membranes that hydrolyzes anandamide into arachidonic acid and ethanolamine. The more active FAAH is, the shorter the lifespan of anandamide in synapses. CBD binds to the active site of FAAH and competitively inhibits its action.

The effect is twofold. First, it directly raises anandamide levels, which itself activates CB1 receptors. This "bypass" means that CBD does not activate CB1 on its own but increases the amount of endogenous agonist. Second, anandamide also acts on TRPV1 and PPAR-gamma, so the effect is broader than just the cannabinoid system.

This is a key argument for why CBD "does not have an overnight effect". FAAH modulation requires regular use, usually 2-4 weeks, for elevated anandamide levels to stabilize in tissues. Therefore, Project CBD recommends assessing effectiveness after at least a month of supplementation (Project CBD, 2023).

Anandamide and its functions in the brain

Anandamide is a neuromodulator with a wide range of effects. It regulates mood, motivation, memory, appetite, pain perception, and stress response. A deficiency of anandamide is associated with symptoms of depression, anxiety, and sleep disorders. Elevated levels produce a "mild euphoria" without intoxication.

An interesting observation: intense physical exertion (running, cycling, swimming for 30+ minutes) increases anandamide levels by 2-3 times. Hence the "runner's high". CBD produces a pharmacologically similar effect but without the need for physical activity. This does not necessarily mean it is a "replacement for exercise", but rather support for individuals with limited mobility.

Why did selective FAAH inhibitors fail in studies?

Pharmaceuticals have attempted to create selective FAAH inhibitors (e.g., BIA 10-2474). One phase 1 study in France in 2016 ended in tragedy – five participants suffered serious neurological complications, and one died. Why? Because complete inhibition of FAAH caused a massive increase in other fatty amides.

CBD partially inhibits FAAH and has self-limiting kinetics. This is why the safety profile of CBD is dramatically better than that of synthetic FAAH inhibitors. In practice, we have a biological "governor" that prevents the mechanism from exceeding physiological limits.

Observation at u Bucha: In a customer survey at u Bucha from Q1 2026 (n=287 respondents), 58% of CBD users reported improvement after 2-4 weeks of regular use, 23% after just one week, and 12% only after 6+ weeks. Only 7% did not notice any effect. This aligns with the literature on the pharmacokinetics of FAAH/anandamide: ECS modulation is a cumulative process, not immediate.

How does CBD interact with GPR55, PPARγ, and other targets?

Beyond the endocannabinoid system, CBD interacts with at least 60 other molecular targets. The most significant for clinical action are GPR55, PPARγ, adenosine receptor A2A, and potassium ion channels (Frontiers in Pharmacology, 2020). This polypharmacology explains the wide therapeutic spectrum of cannabidiol.

GPR55 is the "third cannabinoid receptor" (some researchers propose the name CB3, although this nomenclature has not been officially adopted). It is found in the brain, intestines, adrenal glands, and cancer cells. CBD acts as an antagonist of GPR55. Blocking this receptor has neuroprotective and potentially anti-cancer effects in preclinical models.

PPARγ (peroxisome proliferator-activated receptor gamma) is a nuclear transcription factor. CBD activates PPARγ, which triggers the expression of anti-inflammatory genes and supports the differentiation of fat cells. This mechanism explains the potential neuroprotective action of CBD in neurodegenerative diseases like Alzheimer’s or multiple sclerosis.

Adenosine receptor A2A: CBD inhibits the adenosine transporter ENT1, which increases its extracellular concentration. Higher adenosine stimulates A2A, leading to anti-inflammatory and mildly calming effects. This is why CBD supports sleep, not through a benzodiazepine mechanism, but by modulating adenosine – similar to how caffeine does the opposite.

GPR55 and neuroprotection

GPR55 is strongly activated by lysophosphatidylinositol (LPI). In neurodegenerative diseases and epilepsy, signaling through GPR55 is often excessive, contributing to neuronal excitability and tissue damage. Antagonism of GPR55 by CBD tones down this hyperactivity.

This mechanism is significant in drug-resistant epilepsy. The FDA registered Epidiolex (pure CBD) in 2018 for Dravet and Lennox-Gastaut syndromes precisely because CBD reduces seizure frequency by 30-50% in children unresponsive to other medications (PubMed, 2017). The mechanism involves GPR55, TRPV1, and modulation of voltage-gated calcium channels.

PPARγ and anti-inflammatory effect

PPARγ is the same receptor activated by thiazolidinedione drugs (rosiglitazone, pioglitazone) used in diabetes. CBD acts as a weaker agonist of PPARγ, but strong enough to trigger the expression of anti-inflammatory genes IL-10 and adiponectin, while inhibiting TNF-alpha and IL-6.

In studies on multiple sclerosis, CBD at doses of 20-40 mg/kg reduced symptom severity in animal models. The mechanism involved the activation of PPARγ in brain microglia. Human clinical studies (Sativex – a preparation with CBD and THC) confirm efficacy in spastic MS in about 40% of patients.

Ion channels and calcium gating

CBD blocks voltage-dependent T-type calcium channels, reducing neuronal excitability. This mechanism is common to many anticonvulsant drugs (ethosuximide, valproate). It explains part of CBD's action in epilepsy, independent of GPR55 modulation.

Additionally, CBD activates TASK-1 potassium channels, stabilizing the resting potential of neurons. Neurons become less excitable, but not "dead." This is a subtle modulation, not an aggressive blockade, which explains the good safety profile of CBD compared to classic anticonvulsants.

CBD interacts with at least 65 molecular targets, including GPR55 (antagonism, neuroprotection), PPARγ (agonism, anti-inflammatory action), adenosine receptors A2A (indirectly through ENT1 inhibition), and T-type and TASK-1 ion channels (Frontiers in Pharmacology, 2020). This polypharmacology explains the wide therapeutic spectrum of cannabidiol.

What is the bioavailability of CBD in different forms?

The bioavailability of CBD drastically depends on the route of administration. Orally (capsules, gummies) it is only 6-15%, sublingually 13-19%, and inhaled (vapor) even 31-45% (Frontiers in Pharmacology, 2020). This difference arises from the first-pass effect through the liver and the strong lipophilicity of the molecule. The choice of form affects the speed and strength of action.

Capsules and gummies must pass through the digestive tract and liver. CYP3A4 and CYP2C19 enzymes metabolize a significant portion of CBD to 7-OH-CBD and 7-COOH-CBD before the molecule reaches systemic circulation. The first-pass effect reduces bioavailability to 6-15%. Advantage: slow release, stable blood levels.

Sublingual drops partially bypass the first-pass effect. The mucous membrane under the tongue is richly vascularized, and CBD molecules enter directly into the main vein. Bioavailability increases to 13-19%. Key: hold the oil under your tongue for 60-90 seconds before swallowing. This is the difference between effective and average absorption.

Inhalation (vaporizing dry herb or e-liquids) provides the highest bioavailability. The lungs have a vast gas exchange surface, and CBD enters directly into the pulmonary circulation, bypassing the liver. The effect appears within 2-10 minutes. Disadvantage: shorter duration of action (2-3 hours), requiring more frequent dosing.

Why is the oil form with MCT the most popular?

MCT (medium-chain triglyceride) oils offer the best compromise between bioavailability and convenience. MCT is well soluble, bypasses the lymphatic route (partially bypassing the liver), and increases CBD absorption by 3-5 times compared to pure isolate.

Additionally, MCT has its own health benefits: quick energy for the brain, support for ketone metabolism, antibacterial action of caprylic acid. Therefore, premium CBD oils always use MCT as a carrier, not unrefined sunflower or coconut oil.

How to increase bioavailability?

Several practical strategies. First: take CBD with a fatty meal. Studies show that a high-fat meal increases the AUC (area under the concentration curve) of CBD by up to 4 times compared to fasting administration (Frontiers in Pharmacology, 2020).

Second: use nanoemulsions if available. Nanoemulsions are oils broken down into droplets of 20-200 nanometers. This form increases bioavailability to 40%. They are more expensive but provide a better mg/effect ratio. In Poland, they are still rare, but the first premium products are appearing.

Third: sublingual form, not swallowed. Hold the oil under your tongue for 60-90 seconds. This is the simplest way to double effectiveness without changing the product. Many users make the mistake of swallowing immediately, reducing the oil form to the level of capsules.

How is CBD metabolized and what are the interactions with medications?

CBD is primarily metabolized in the liver by cytochrome P450 enzymes, mainly CYP3A4 (about 60% of metabolism) and CYP2C19 (about 30%). CBD simultaneously inhibits these same enzymes, which affects the metabolism of about 60% of drugs available on the market (PMC, 2019). This is a source of clinically significant drug interactions.

The mechanism is competitive. Both CBD and many drugs (warfarin, statins, benzodiazepines, proton pump inhibitors) use the same enzymes. When we administer CBD at a dose of 20+ mg simultaneously with a drug metabolized by CYP3A4, the enzyme becomes saturated. The drug remains longer in the bloodstream, and its concentration increases.

Clinical consequences. Warfarin: potential enhancement of anticoagulant action, necessary monitoring of INR. Statins: increased risk of myopathy. Benzodiazepines: intensified sedation. Some anticonvulsants (clobazam, valproate): significant interactions requiring dose adjustment (PubMed, 2018).

The half-life of CBD is 18-32 hours after oral administration and 18-31 hours after inhalation. This means that with regular use, steady state is reached in 4-7 days. Only then can the therapeutic effect and potential interactions with other medications be realistically assessed.

Table of the most important CBD drug interactions

Group one – high risk of interactions. Warfarin (monitor INR, possible dose reduction by 30%), clobazam (increase in N-desmethylclobazam 3-5 times, drowsiness), valproate (increased hepatotoxicity), some chemotherapies (tamoxifen, paclitaxel – change in metabolite activity).

Group two – moderate risk. Statins (atorvastatin, simvastatin), proton pump inhibitors (omeprazole, pantoprazole), benzodiazepines (alprazolam, diazepam), some SSRIs (sertraline, citalopram). With regular CBD supplementation above 20 mg per day, it is advisable to inform your doctor.

Group three – low risk, but monitoring is advisable. Metformin, levothyroxine, antihypertensives, hormonal contraception. For most patients, CBD supplementation of 20-50 mg per day is safe, but each case should be discussed with a pharmacist, especially if taking more than 2 medications simultaneously.

How to minimize the risk of interactions?

First: separate in time. Take CBD at least 2 hours before or after medications. This does not eliminate interactions but reduces the peak of simultaneous enzyme saturation. Second: start with a low dose of CBD (10 mg daily) and observe if the effects of medications change. Third: inform your doctor about CBD supplementation.

Many patients treat CBD as "herbs" rather than an active pharmacological compound. This is a mistake. CBD has real pharmacokinetic effects. Consulting with a doctor or pharmacist is not a formality – it is a practical tool for avoiding serious complications, especially in oncological, cardiological, and psychiatric therapies.

What is the entourage effect and why does it enhance the action of CBD?

The entourage effect was described in 2011 in the British Journal of Pharmacology by Russo and Mechoulam (British Journal of Pharmacology, 2011). This is a synergy between cannabinoids, terpenes, and flavonoids found in cannabis. A full-spectrum preparation works more powerfully than the sum of its individual components – a phenomenon of more than 2+2=4.

The mechanism is multi-layered. Beta-caryophyllene (a terpene, but also a CB2 agonist) enhances the anti-inflammatory action of CBD. Myrcene increases the permeability of the blood-brain barrier, facilitating CBD's access to the CNS. Linalool (as in lavender) supports the anxiolytic action of 5-HT1A. Limonene improves mood through noradrenergic modulation.

Other cannabinoids add their own mechanisms. CBG weakly activates CB1 and CB2 and alpha-2 adrenergic receptors. CBN has sedative effects that enhance sleep. CBC acts on TRPA1 and inhibits FAAH synergistically with CBD. Even trace amounts of THC (up to 0.3% in full-spectrum products) activate CB1 in a way that is allosterically suppressed by CBD.

Therefore, full-spectrum and broad-spectrum oils are usually more effective than CBD isolates. A comparative study from 2018 showed that to achieve the same anti-inflammatory effect, 4 times more CBD isolate is needed than full-spectrum extract (Cannabis and Cannabinoid Research, 2018).

Broad spectrum vs full spectrum vs isolate.

Full spectrum contains all cannabinoids and terpenes from the plant, including trace THC up to 0.3%. Maximum entourage effect, legal in Poland, but theoretically possible detection of THC in a drug test with very frequent and high dosing.

Broad spectrum contains all cannabinoids and terpenes except THC. A good compromise: almost full entourage effect, zero risk of drug testing. This is the form most often chosen by Polish users, especially athletes and professional drivers.

Isolate is 99% pure CBD, without other cannabinoids and terpenes. The weakest effect per milligram, but precise dosing. Used in clinical studies (where the entourage effect complicates interpretation) and in individuals with allergies to terpenes. In daily supplementation, isolate has limited advantages.

The role of terpenes in modulating CBD effects

Terpenes are aromatic compounds found in cannabis, lavender, chamomile, citrus fruits, and conifers. Myrcene dominates in high-THC cannabis, providing a relaxing effect. Pinene improves concentration and clarity of mind. Limonene enhances mood through serotonin modulation. Linalool has anxiolytic and analgesic effects.

Therefore, the terpene profile of CBD oil matters. A product with higher myrcene will be more "calming," while one with higher limonene will be more "energizing." Many premium manufacturers publish terpene profiles in the certificate of analysis (COA). Look for this data before buying CBD oil for a specific purpose.

The entourage effect described in 2011 is the synergy between cannabinoids, terpenes, and flavonoids from cannabis (British Journal of Pharmacology, 2011). A comparative study showed that CBD isolate requires 4 times higher doses than full-spectrum extract to achieve the same anti-inflammatory effect (Cannabis and Cannabinoid Research, 2018).

How to dose CBD to activate mechanisms of action?

Dosing CBD depends on the purpose of supplementation and individual sensitivity of the ECS. Typical starting doses are 10-20 mg daily, increased every 3-7 days. The WHO in a 2018 review rated CBD as well-tolerated up to 1500 mg daily (WHO, 2018). In practical supplementation, doses of 20-50 mg cover most applications.

The dose-effect curve for CBD has the shape of an inverted U. In the study by Linares et al. on social anxiety, a dose of 300 mg produced a better effect than 150 mg and 600 mg (Frontiers in Pharmacology, 2019). This is typical for allosteric modulators, in contrast to classical linear agonists.

Practical consequence: do not automatically increase the dose if the effect is too weak. Find your "optimal zone" and stick to it. Exceeding the optimum usually results in a weaker effect, not a stronger one. The principle of "start low, go slow" applies to all cannabinoids.

Typical doses in specific scenarios

Anxiety and stress: 20-50 mg of CBD daily, divided into 2-3 doses, for at least 4 weeks. Sublingually, with a meal containing fat. Studies suggest an optimal effect in the range of 25-75 mg for individuals with moderate anxiety (The Permanente Journal, 2019).

Sleep and insomnia: 40-60 mg of CBD 1-2 hours before bedtime. Preferred full-spectrum preparations with CBN. The effect builds up over 2-3 weeks. In a 2019 survey, 66.7% of respondents reported improved sleep after a month. There is no "sleeping pill" effect – CBD normalizes sleep rather than forcing sleep.

Chronic pain: 20-40 mg of CBD orally + topical preparations for local pain (CBD ointments, balms). For peripheral neuropathy, doses of 250 mg/day topically are effective. A combination of oral and topical provides the best effect due to different mechanisms (systemic TRPV1 vs local).

Drug-resistant epilepsy (only under medical supervision): 5-20 mg/kg of body weight daily, divided into 2 doses. These are Epidiolex doses that require monitoring of liver function and interactions with other anticonvulsants. This is not a supplementation scheme, but a medical one.

When to take CBD – in the morning or evening?

Flexibly, depending on the dose and purpose. Low doses (5-15 mg) can be taken in the morning, as they do not induce sedation. Medium doses (20-40 mg) are preferred in the evening, especially if you are seeking sleep support. High doses (50+ mg) are usually divided into 2-3 portions daily for stable blood levels.

For optimal FAAH/anandamide effect, I recommend a consistent schedule. The body responds better to regularity than to large single doses. Take CBD at a similar time each day for at least a month before assessing effectiveness. ECS modulation is a cumulative process.

From the Bucha editorial office: Over the last 24 months, we have observed thousands of orders and customer inquiries. The most common mistake is "I started with 50 mg and it doesn't work." Meanwhile, lower doses (10-20 mg) often yield better results than higher ones. The second mistake: evaluating after 3 days. It takes at least 2-4 weeks to see the full effect of modulating the endocannabinoid system. The third mistake: swallowing immediately instead of holding under the tongue for 60-90 seconds.

What are the documented therapeutic effects of CBD?

CBD is one of the most intensively studied cannabinoids. By 2024, over 300 randomized placebo-controlled studies have been conducted (PubMed, 2024). The strongest evidence pertains to epilepsy (Epidiolex registered by the FDA), anxiety, insomnia, chronic pain, and selected inflammatory skin diseases.

Drug-resistant epilepsy. Epidiolex reduces seizure frequency by 30-50% in Dravet, Lennox-Gastaut, and tuberous sclerosis syndromes. The FDA approved the drug in 2018. Doses of 10-20 mg/kg daily. This is the most well-documented indication for CBD in the world (PubMed, 2017).

Generalized and social anxiety. Doses of 25-600 mg daily reduce anxiety symptoms by 40-80% in various studies. Mechanism: 5-HT1A, FAAH, GABA-ergic modulation. The effect is comparable to buspirone but with a better safety profile. It does not induce sedation or addiction like benzodiazepines.

Insomnia and sleep quality. 66% improvement in sleep after a month of supplementation with 25-175 mg of CBD daily. The mechanism involves GABA-ergic modulation, adenosine A2A, and indirectly melatonin. CBD does not force sleep but normalizes sleep architecture, particularly REM and deep slow-wave sleep.

Chronic pain and inflammatory states

The Cochrane review from 2020 assesses the evidence for the analgesic effects of cannabinoids as "moderate." In neuropathic pain and pain associated with cancer, CBD reduces intensity by 20-40%. The mechanism involves TRPV1, alpha-3 glycine receptor, FAAH modulation, and PPARγ.

Joint inflammatory states: in a 2022 study, topical CBD 250-750 mg/day reduced pain in patients with knee osteoarthritis by 40% compared to placebo. The effect lasted for 12 weeks. Source: double-blind RCT (PubMed, 2022).

Neurological and neurodegenerative disorders

Parkinson's disease: CBD at doses of 150-300 mg daily improved quality of life and reduced extrapyramidal symptoms (anxiety, sleep problems) in small clinical studies. The mechanism involves PPARγ and antioxidant action. It has no effect on classical motor symptoms such as tremors or stiffness.

Multiple sclerosis: Sativex (CBD + THC 1:1) reduces spasticity in about 40% of patients. Pure CBD without THC has a weaker effect but supports the control of neuropathic pain typical of MS. The European Medicines Agency (EMA) approved Sativex in 2010.

Skin issues: acne and atopic dermatitis

A 2014 study showed that CBD in human sebocytes inhibits sebum production and reduces inflammation caused by Propionibacterium acnes (PubMed, 2014). The mechanism involves the TRPV4 receptor and PPARγ. CBD acts on two causes of acne simultaneously, which explains the popularity of CBD cosmetics.

Atopic dermatitis: topical preparations with 3-5% CBD reduce itching and erythema by 30-50% in observational studies. Mechanism: modulation of vanilloid receptors in the skin and inhibition of inflammatory mediators. They do not replace steroids in severe cases but support therapy for mild and moderate forms.

What are the side effects of CBD and when to be cautious?

CBD has a good safety profile but is not free from side effects. In the WHO review from 2018, the most common adverse effects are fatigue, diarrhea, changes in appetite, and changes in body weight (WHO, 2018). Dry mouth and dizziness occur less frequently. Severe adverse effects are rare.

Most common, mild: drowsiness (8-15% of users), dry mouth (10-12%), diarrhea or changes in stool consistency (5-8%), changes in appetite (5%), headaches (3-5%). Most symptoms resolve within 1-2 weeks of regular use or after reducing the dose by 50%.

Rare but significant: elevation of liver enzymes (ALT, AST) in about 10-15% of patients using high doses (>20 mg/kg). Monitoring is required with long-term use above 50 mg daily. Drug interactions: clinically significant for warfarin, clonazepam, statins.

CBD does not exhibit addictive potential, as confirmed by studies from WHO and FDA. No tolerance, no withdrawal syndrome, no "craving" episodes. This is a key difference compared to benzodiazepines, opioids, and some antidepressants.

Who should not use CBD?

Pregnancy and breastfeeding. Insufficient safety data. CBD crosses the placenta and enters breast milk. Preclinical studies suggest a possible impact on fetal brain development. Absolute lack of consultation – if the doctor does not recommend it, do not use.

Severe liver diseases. CBD is metabolized in the liver; high doses may worsen liver function in patients with cirrhosis or active inflammation. In mild liver insufficiency, reduce doses by 50%. Always under medical supervision.

Children and adolescents (under 18 years). Use only for registered indications (Epidiolex in epilepsy, under the supervision of a neurologist). Supplementary CBD outside of epilepsy lacks sufficient long-term safety data in the young brain.

When to stop CBD immediately?

Jaundice (yellowing of the skin or whites of the eyes). Symptoms of a severe allergic reaction (swelling, shortness of breath, rash). Significant mental deterioration (intensified anxiety, suicidal thoughts – very rare, but possible). Significant changes in the action of other medications. Always consult with a doctor before stopping medication therapy due to CBD.

Frequently Asked Questions

How does CBD work in the human body?

CBD works indirectly through the endocannabinoid system (ECS) and over 65 other molecular targets. It does not directly activate CB1 receptors but modulates them allosterically, inhibits the FAAH enzyme (raising anandamide levels), stimulates the 5-HT1A receptor (anxiolytic effect), and TRPV1 (pain regulation). The lack of psychoactive effect results from a different mechanism than THC (Frontiers in Pharmacology, 2020).

Why is CBD not psychoactive like THC?

CBD has minimal orthosteric affinity for the CB1 receptor and additionally acts as its negative allosteric modulator. This means that CBD not only does not activate CB1 but also weakens the action of THC when taken simultaneously. The CB1 receptor is responsible for the psychoactive effects of cannabinoids, which is why CBD remains non-intoxicating (British Journal of Pharmacology, 2015).

How does CBD affect the endocannabinoid system?

CBD indirectly enhances the action of the endogenous cannabinoid system. It inhibits the FAAH enzyme that breaks down anandamide, raising the level of this endocannabinoid in the body by 30-106% depending on the dose (Translational Psychiatry, 2012). At the same time, it acts as a negative allosteric modulator of CB1 and CB2, meaning it regulates their sensitivity without direct activation.

What receptors besides CB1 and CB2 does CBD act on?

CBD interacts with over 65 molecular targets. The most important are the 5-HT1A receptor (anxiolysis, antidepressant action), TRPV1 (pain and temperature), GPR55 (neuroprotection), PPARγ (anti-inflammatory action, neuroprotection), and the alpha-3 glycine receptor (modulation of neuropathic pain). This multi-directional activity explains the wide therapeutic spectrum of CBD (Frontiers in Pharmacology, 2020).

How is CBD metabolized in the body?

CBD is primarily metabolized in the liver by cytochrome P450 enzymes, mainly CYP3A4 and CYP2C19. CBD inhibits these same enzymes, which may affect the metabolism of about 60% of drugs available on the market (PMC, 2019). Oral bioavailability is 6-19%, and the sublingual form reaches the upper limit of this range. The half-life is in the range of 18-32 hours.

How long does it take for CBD to start working?

The time to effect depends on the form of administration. Sublingually, CBD works after 15-45 minutes, capsules and gummies after 60-120 minutes, vapors after 2-10 minutes. Bioavailability ranges from 6% (oral) to 19% (sublingual) and up to 31-45% (inhalation). The full effect of ECS modulation reveals itself after 2-4 weeks of regular supplementation (Project CBD, 2023).

Does CBD inhibit the FAAH enzyme and increase anandamide levels?

Yes. CBD inhibits fatty acid amide hydrolase (FAAH), the enzyme that breaks down anandamide, often referred to as the happiness hormone. In the study by Leweke et al. (Translational Psychiatry, 2012), supplementation with 600-800 mg of CBD daily raised anandamide levels in the serum of patients with psychosis by 106%. This mechanism explains part of the anxiolytic and antidepressant action of CBD.

Can CBD interact with medications?

Yes. CBD inhibits cytochrome P450 enzymes, mainly CYP3A4 and CYP2C9, which metabolize about 60% of drugs. Clinically significant interactions involve warfarin, some anticonvulsants (clobazam, valproate), statins, benzodiazepines, and proton pump inhibitors (PMC, 2019). Before combining CBD with medications, consult your doctor or pharmacist, especially at doses above 20 mg daily.

Summary: how does CBD work and what does it mean?

CBD is a polypharmacological modulator of many systems in the body. It acts through the endocannabinoid system (inhibition of FAAH, allosteric modulation of CB1/CB2), serotonergic (5-HT1A), vanilloid (TRPV1), glycinergic, transcriptional (PPARγ), and others. This multifaceted activity explains the wide therapeutic spectrum and the absence of a simple scheme of "how CBD works."

Key differences compared to THC: CBD does not directly activate CB1, is a negative allosteric modulator, does not produce a psychoactive effect. The WHO rated it as safe up to 1500 mg daily, with no potential for addiction. This makes CBD an attractive health support tool without the risks typical of classical psychotropic drugs.

For the practical user: start with a low dose (10-20 mg), use regularly for at least 4 weeks, choose broad spectrum oils with MCT, hold sublingually for 60-90 seconds, observe effects, and adjust the dose. When taking medications, consult your doctor or pharmacist, especially if using warfarin, statins, benzodiazepines, or anticonvulsants.

The science of CBD evolves every year. New publications changing our perspective appear every 6 months. At u Bucha, we strive to track research and translate it into practical tips for Polish users, based on current literature and personal experience with thousands of clients. Cannabidiol is not a magic pill, but a proven tool with a well-described mechanism of action.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 23, 2026
Last update: April 23, 2026